Millendo Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating income was USD 6.056 million compared to USD 11.751 million a year ago. Net loss was USD 6.374 million compared to USD 11.632 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.87 a year ago. For the nine months, operating income was USD 28.795 million compared to USD 32.568 million a year ago. Net loss was USD 29.044 million compared to USD 31.869 million a year ago. Basic loss per share from continuing operations was USD 1.54 compared to USD 2.38 a year ago.